IP-10 release assays in the diagnosis of tuberculosis infection: Current status and future directions

Expert Review of Molecular Diagnostics

Volumn 12, Issue 2, 2012, Pages 175-187

  Ruhwald, Morten ^a   Aabye, Martine G ^a   Ravn, Pernille ^a,b  

^a Mental Health Services CPH   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CXCL10; IFN ; IGRA; IP 10; latent TB infection; tuberculosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; METHOTREXATE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; CHILDHOOD MORTALITY; CROSS REACTION; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MORBIDITY; MULTICENTER STUDY (TOPIC); MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SUPERNATANT; TUBERCULIN TEST; TUBERCULOSIS;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; COINFECTION; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; TUBERCULOSIS, PULMONARY;

EID: 84857949606     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.97     Document Type: Review

References (121)

1. Dorhoi A, Reece ST, Kaufmann SHE. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol. Rev. 240(1), 235-251 (2011).
2. Lawn SD, Zumla AI. Tuberculosis. Lancet 378(9785), 57-72 (2011).
3. Kaufmann SHE. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 11(8), 633-640 (2011).
4. Grant AD, Charalambous S, Fielding KL et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 293(22), 2719-2725 (2005). (Pubitemid 40965083)
5. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 356(9235), 1099-1104 (2000).
6. Lalvani A, Pareek M. A 100 year update on diagnosis of tuberculosis infection. Br. Med. Bull. 93, 69-84 (2010).
7. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-g release assays and childhood tuberculosis: systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 15(8), 1018-1032 (2011).
8. Sester M, Sotgiu G, Lange C et al. Interferon-g release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 37, 100-111 (2011).
9. Diel R, Goletti D, Ferrara G et al. Interferon-g release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur. Respir. J. 37(1), 88-99 (2011).
10. Kabeer BSA, Sikhamani R, Raja A. Comparison of interferon g-inducible protein-10 and interferon g-based Quanti FERON TB Gold assays with tuberculin skin test in HIV-infected subjects. Diagn. Microbiol. Infect. Dis. 71(3), 236-243 (2011).
11. Cattamanchi A, Smith R, Steingart KR et al. Interferon-g release assays for the diagnosis of latent tuberculosis infection in HIVinfected individuals: a systematic review and meta-analysis. J. Acquired Immune Defic. Syndromes 56(3), 230-238 (2011).
12. Bélard E, Semb S, Ruhwald M et al. Prednisolone treatment affects the performance of the Quanti FERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm. Bowel Dis. 17(11), 2340-2349 (2011).
13. Aabye MG, Ravn P, PrayGod G et al. The impact of HIV infection and CD4 cell count on the performance of an interferon g release assay in patients with pulmonary tuberculosis. PLoS One 4(1), e4220 (2009).
14. Aichelburg MC, Rieger A, Breitenecker F et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-g release assay in HIV-1-infected individuals. Clin. Infect. Dis. 48(7), 954-962 (2009).
15. Søborg B, Andersen AB, Melbye M et al. Risk factors for Mycobacterium tuberculosis infection among children in Greenland. Bull. WHO 89(10), 741E-748E (2011).
16. Lange C, Rieder HL. Intention to test is intention to treat. Am. J. Respir. Crit. Care Med. 183(1), 3-4 (2011).
17. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Kofoed K, Eugen-Olsen J, Ravn P. IP-10/CXCL10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect. 9(7), 806-812 (2007). (Pubitemid 46901043)
18. Bibova I, Linhartova I, Stanek O et al. Detection of immune cell response to M. tuberculosis-specific antigens by quantitative polymerase chain reaction. Diagn. Microbiol. Infect. Dis. 72(1), 68-72 (2012).
19. Chegou N, Black G, Kidd M, van Helden P, Walzl G. Host markers in Quanti FERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulmonary Med. 9(1), 21 (2009).
20. Frahm M, Goswami ND, Owzar K et al. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis 91(3), 250-256 (2011).
21. Hasan Z, Rao N, Salahuddin N et al. M. tuberculosis sonicate induced IFNg, CXCL10 and IL10 can differentiate severity in tuberculosis. Scand. J. Immunol. doi:10.1111/j.1365-3083.2011.02642.x (2011) (Epub ahead of print).
22. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res. Notes 2(1), 19 (2009).
23. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MOC. Production of TNF-a, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 5(8), e12365 (2010).
24. Kellar KL, Gehrke J, Weis SE et al. Multiple cytokines are released when blood from patients with tuberculosis is stimulated with mycobacterium tuberculosis antigens. PLoS One 6(11), e26545 (2011).
25. Lighter-Fisher J, Peng CH, Tse DB. Cytokine responses to QuantiFERON® peptides, purified protein derivative and recombinant ESAT-6 in children with tuberculosis. Int. J. Tuberc. Lung Dis. 14(12), 1548-1555 (2010).
26. Nemeth J, Winkler HM, Boeck L et al. Specific cytokine patterns of pulmonary tuberculosis in Central Africa. Clin. Immunol. 138(1), 50-59 (2011).
27. Li L, Qiao D, Fu X, Lao S, Zhang X, Wu C. Identification of Mycobacterium tuberculosis-specific Th1, Th17 and Th22 cells using the expression of CD40L in tuberculous pleurisy. PLoS One 6(5), e20165 (2011).
28. Chegou NN, Hoek KGP, Kriel M, Warren RM, Victor TC, Walzl G. Tuberculosis assays: past, present and future. Expert Rev. Anti Infect. Ther. 9(4), 457-469 (2011).
29. Lalvani A, Millington KA. T-cell interferon-g release assays: can we do better? Eur. Respir. J. 32(6), 1428-1430 (2008).
30. Lalvani A, Pareek M. Interferon g release assays: principles and practice. Enferm. Infecc. Microbiol. Clin. 28(4), 245-252 (2010).
31. Lange C, Mori T. Advances in the diagnosis of tuberculosis. Respirology 15(2), 220-240 (2010).
32. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 11(5), 343-354 (2011).
33. van der Werf MJ, van Leth F. Latent tuberculosis infection and interferon-g release assays: what new knowledge did we gain through the Journal in 2009? Int. J. Tuberc. Lung Dis. 14(12), 1525-1529 (2010).
34. Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J. Infect. Dis. 204(Suppl. 4), S1168-S1178 (2011).
35. Dhillon NK, Peng F, Ransohoff RM, Buch S. PDGF Synergistically enhances IFN-g-induced expression of CXCL10 in blood-derived macrophages: implications for HIV dementia. J. Immunol. 179(5), 2722-2730 (2007).
36. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2(2), 123-128 (2001). (Pubitemid 33707929)
37. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89(2), 207-205 (2011).
38. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61(3), 246-257 (1997). (Pubitemid 27149903)
39. Narumi S, Finke JH, Hamilton TA. Interferon g and interleukin 2 synergize to induce selective monokine expression in murine peritoneal macrophages. J. Biol. Chem. 265(12), 7036-7041 (1990).
40. Sauty A, Dziejman M, Taha RA et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J. Immunol. 162(6), 3549-3558 (1999). (Pubitemid 29313608)
41. Karonitsch T, Dalwigk K, Steiner CW et al. Interferon (IFN) signals and monocytic sensitization of the IFNg signaling pathway in peripheral blood of rheumatoid arthritis patients. Arthritis Rheum. doi:10.1002/art.33347 (2011) (Epub ahead of print).
42. Ohmori Y, Wyner L, Narumi S, Armstrong D, Stoler M, Hamilton TA. Tumor necrosis factor-a induces cell type and tissuespecific expression of chemoattractant cytokines in vivo. Am. J. Pathol. 142(3), 861-870 (1993). (Pubitemid 24064004)
43. Guzzo C, Che Mat NF, Gee K. Interleukin-27 induces a STAT1/3- and NF-kB-dependent proinflammatory cytokine profile in human monocytes. J. Biol. Chem. 285(32), 24404-24411 (2010).
44. Rudner XL, Happel KI, Young EA, Shellito JE. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun. 75(6), 3055-3061 (2007). (Pubitemid 46870190)
45. Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8(4), 369-377 (2007). (Pubitemid 46745412)
46. Qian C, An H, Yu Y, Liu S, Cao X. TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. Blood 109(8), 3308-3315 (2007). (Pubitemid 46572518)
47. Chen J, Liu X. The role of interferon g in regulation of CD4+ T-cells and its clinical implications. Cell Immunol. 254(2), 85-90 (2009).
48. Farrar MA, Schreiber RD. The molecular cell biology of interferon-g and its receptor. Annu. Rev. Immunol. 11, 571-611 (1993). (Pubitemid 23115018)
49. Aabye MG, Ravn P, Johansen IS, Eugen-Olsen J, Ruhwald M. Incubation of whole blood at 39°C augments IP-10 and IFN-g responses to M. tuberculosis antigens. Clin. Vaccine Immunol. 18(7), 1150-1156 (2011).
50. Goletti D, Raja A, Kabeer BSA et al. IFN-[g], but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J. Infect. 61(2), 133-143 (2010).
51. Kabeer BSA, Raja A, Raman B et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect. Dis. 11, 135 (2011).
52. Ruhwald M, Bodmer T, Maier C et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur. Respir. J. 32(6), 1607-1615 (2008).
53. Ruhwald M, Dominguez J, Latorre I et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis 91(3), 260-267 (2011).
54. Kabeer BSA, Raman B, Thomas A, Perumal V, Raja A. Role of QuantiFERON-TB gold, interferon g inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 5(2), e9051 (2010).
55. Aabye MG, Ruhwald M, Praygod G et al. Potential of interferon-{g}- inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur. Respir. J. 36(6), 1488-1490 (2010).
56. Goletti D, Raja A, Kabeer BSA et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIVinfected persons? PLoS One 5(9), e12577 (2010).
57. Chintu C, Mudenda V, Lucas S et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 360(9338), 985-990 (2002). (Pubitemid 35284110)
58. McNally LM, Jeena PM, Gajee K et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 369(9571), 1440-1451 (2007). (Pubitemid 46635781)
59. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am. J. Respir. Crit. Care Med. 173(10), 1078-1090 (2006). (Pubitemid 43726888)
60. Marais BJ, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr. Respir. Rev. 8(2), 124-133 (2007). (Pubitemid 46900102)
61. Yassin MA, Petrucci R, Garie KT et al. Can interferon-g or interferon-g-inducedprotein- 10 differentiate tuberculosisinfection and disease in children of high endemic areas? PLoS One 6(9), e23733 (2011).
62. Alsleben N, Ruhwald M, Rüssmann H, Marx FM, Wahn U, Magdorf K. Interferon-g inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case- control study. Scand. J. Infect. Dis. doi:10.31 09/00365548.2011.632644 (2011).
63. Lighter J, Rigaud M, Huie M, Peng CH, Pollack H. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int. J. Tuberc. Lung Dis. 13(6), 731-736 (2009).
64. Ruhwald M, Petersen J, Kofoed K et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 3(8), e2858 (2008).
65. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y et al. The utility of an interferon g release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and metaanalysis. Pediatr. Infect. Dis. J. 30(8), 694-700 (2011).
66. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 1, CD000171 (2010).
67. Santin M, Casas S, Saumoy M et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-g release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn. Microbiol. Infect. Dis. 69(1), 59-65 (2011).
68. Latorre I, Martínez-Lacasa X, Font R et al. IFN-g response on T-cell based assays in HIV-infected patients for detection of tuberculosis infection. BMC Infect. Dis. 10, 348 (2010).
69. Leidl L, Mayanja-Kizza H, Sotgiu G et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur. Respir. J. 35(3), 619-626 (2010).
70. Kabeer BSA, Sikhamani R, Swaminathan S, Perumal V, Paramasivam P, Raja A. Role of interferon g release assay in active TB diagnosis among HIV infected individuals. PLoS One 4(5), e5718 (2009).
71. Raby E, Moyo M, Devendra A et al. The effects of HIV on the sensitivity of a whole blood IFN-g release assay in Zambian adults with active tuberculosis. PLoS One 3(6), e2489 (2008).
72. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-g test. Respir. Res. 7, 56 (2006).
73. Kabeer BS, Sikhamani R, Raja A. Comparison of interferon g and interferon g-inducible protein-10 secretion in HIV-tuberculosis patients. AIDS 24(2), 323-325 (2010).
74. Sutherland JS, Young JM, Peterson KL et al. Polyfunctional CD4+ and CD8+ T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J. Immunol. 184(11), 6537-6544 (2010).
75. Qi XF, Kim DH, Yoon YS et al. Essential involvement of cross-talk between IFN-g and TNF-a in CXCL10 production in human THP-1 monocytes. J. Cell. Physiol. 220(3), 690-697 (2009).
76. Solovic I, Sester M, Gomez-Reino JJ et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur. Respir. J. 36(5), 1185-1206 (2010).
77. Bélard E, Semb S, Ruhwald M et al. Prednisolone treatment affects the performance of the Quanti FERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm. Bowel Dis. 17(11), 2340-2349 (2011).
78. Chen DY, Shen GH, Chen YM et al. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis. Int. J. Tuberc. Lung Dis. 15(2), 192-200 (2011).
79. Lei HY, Chang CP. Lectin of concanavalin A as an anti-hepatoma therapeutic agent. J. Biomed. Sci. 16, 10 (2009).
80. Itoh Y, Morita A, Nishioji K et al. Time course profile and cell-type-specific production of monokine induced by interferon-g in concanavalin A-induced hepatic injury in mice: comparative study with interferon-inducible protein-10. Scand. J. Gastroenterol. 36(12), 1344-1351 (2001). (Pubitemid 33027816)
81. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-g release assays for tuberculosis infection: concordance, discordance or confusion? Clin. Microbiol. Infect. 17(6), 806-814 (2011).
82. Sester M, Sotgiu G, Lange C et al. Interferon-g release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 37(1), 100-111 (2011).
83. Goletti D, Carrara S, Butera O et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNETStudy. PLoS One 3(10), e3417 (2008).
84. Skogstrand K, Thorsen P, Nørgaard-Pedersen B, Schendel DE, Sørensen LC, Hougaard DM. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin. Chem. 51(10), 1854-1866 (2005). (Pubitemid 41368176)
85. Geluk A, van der Ploeg-van Schip JJ, van Meijgaarden KE et al. Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays. Clin. Vaccine Immunol. 17(6), 993-1004 (2010).
86. Chen J, Wang S, Zhang Y et al. Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls. BMC Infect. Dis. 10, 273 (2010).
87. Millington KA, Fortune SM, Low J et al. Rv3615c is a highly immunodominant RD1 (region of difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 108(14), 5730-5735 (2011).
88. Bertholet S, Horne DJ, Laughlin EM et al. Effect of chemotherapy on whole blood cytokine profiles to Mycobacterium tuberculosis antigens in a small cohort of pulmonary tuberculosis patients. Clin. Vaccine Immunol. 18(8) 1378-1386 (2011).
89. Goletti D, Butera O, Vanini V et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur. Respir. J. 36(1), 135-142 (2010).
90. Schuck SD, Mueller H, Kunitz F et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS One 4(5), e5590 (2009).
91. Chiacchio T, Petruccioli E, Vanini V et al. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One 6(11), e27539 (2011).
92. Butera O, Chiacchio T, Carrara S et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect. Dis. 9, 182 (2009).
93. Leyten EM, Lin MY, Franken KL et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 8(8), 2052-2060 (2006). (Pubitemid 44311602)
94. Denis M, Wedlock DN, McCarthy AR et al. Enhancement of the sensitivity of the whole-blood g interferon assay for diagnosis of Mycobacterium bovis infections in cattle. Clin. Vaccine Immunol. 14(11), 1483-1489 (2007). (Pubitemid 350304043)
95. Feske ML, Medina M, Graviss EA, Lewis DE. IL-7 addition increases spot size and number as measured by T-SPOT.TB(®). Methods Mol. Biol. 792, 229-241 (2012).
96. Feske M, Nudelman RJ, Medina M et al. Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. Clin. Vaccine Immunol. 15(10), 1616-1622 (2008).
97. Mei JV, Zobel SD, Hall EM, De Jesús VR, Adam BW, Hannon WH. Performance properties of filter paper devices for whole blood collection. Bioanalysis 2(8), 1397-1403 (2010).
98. Kasprowicz VO, Mitchell JE, Chetty S et al. A molecular assay for sensitive detection of pathogen-specific T-cells. PLoS One 6(8), e20606 (2011).
99. Chakera A, Bennett SC, Cornall RJ. A whole blood monokine-based reporter assay provides a sensitive and robust measurement of the antigen-specific T cell response. J. Translat. Med. 9(1), 143 (2011).
100. Lange B, Vavra M, Kern M, Wagner D. IP-10 measurement using a point of care test for the diagnosis of active tuberculosis. Presented at: The European Respiratory Society Annual Congress. Amsterdam, The Netherlands, 24-28 September 2011 (Abstract #1900).
101. Su WL, Perng WC, Huang CH, Yang CY, Wu CP, Chen JH. Association of reduced tumor necrosis factor a, g interferon, and interleukin-1b (IL-1b) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin. Vaccine Immunol. 17(2), 223-231 (2010).
102. Lu C, Wu J, Wang H et al. Novel biomarkers distinguishing active tuberculosis from latent infection identified by gene expression profile of peripheral blood mononuclear cells. PLoS One 6(8), e24290 (2011).
103. Berry MPR, Graham CM, McNab FW et al. An interferon-inducible neutrophildriven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010).
104. Azzurri A, Sow OY, Amedei A et al. IFN-g-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 7(1), 1-8 (2005). (Pubitemid 40431338)
105. Casrouge A, Decalf J, Ahloulay M et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121(1), 308-317 (2011).
106. Zeremski M, Hooker G, Shu MA et al. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J. Hepatol. 55(3), 545-553 (2011).
107. Askarieh G, Alsiö A, Pugnale P et al. Systemic and intrahepatic interferon-ginducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 51(5), 1523-1530 (2010).
108. Ng PC, Li K, Chui KM et al. IP-10 is an early diagnostic marker for identification of late-onset bacterial infection in preterm infants. Pediatr. Res. 61(1), 93-98 (2007). (Pubitemid 46352323)
109. Punyadeera C, Schneider EM, Schaffer D et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J. Emerg. Trauma Shock 3(1), 26-35 (2010).
110. Olszyna DP, Prins JM, Dekkers PE et al. Sequential measurements of chemokines in urosepsis and experimental endotoxemia. J. Clin. Immunol. 19(6), 399-405 (1999). (Pubitemid 30039107)
111. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory ediators in chronic hepatitis C virus infection. J. Viral Hepat. 14(10), 675-687 (2007). (Pubitemid 47414927)
112. Ng PC, Lam CWK, Li AM et al. Chemokine response in children with SARS. Arch. Dis. Child 90(4), 422-423 (2005). (Pubitemid 40488686)
113. Bai X, Wilson SE, Chmura K, Feldman NE, Chan ED. Morphometric analysis of Th(1) and Th(2) cytokine expression in human pulmonary tuberculosis. Tuberculosis 84(6), 375-385 (2004). (Pubitemid 39451904)
114. Pokkali S, Das SD, R L. Expression of CXC and CC type of chemokines and its receptors in tuberculous and nontuberculous effusions. Cytokine 41(3), 307-314 (2008). (Pubitemid 351308157)
115. Dheda K, Van-Zyl Smit RN, Sechi LA et al. Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PLoS One 4(3), e4689 (2009).
116. Cannas A, Calvo L, Chiacchio T et al. IP-10 detection in urine is associated with lung diseases. BMC Infect. Dis. 10, 333 (2010).
117. Hang NTL, Lien LT, Kobayashi N et al. Analysis of factors lowering sensitivity of interferon-g release assay for tuberculosis. PLoS One 6(8), e23806 (2011).
118. Li L, Qiao D, Zhang X, Liu Z, Wu C. The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells. Immunobiology 216(4), 477-484 (2011).
119. Rueda CM, Marín ND, García LF, Rojas M. Characterization of CD4 and CD8 T cells producing IFN-g in human latent and active tuberculosis. Tuberculosis 90(6), 346-353 (2010).
120. Petrucci R, Abu AN, Gurgel RQ et al. Interferon g, interferon-g-induced- protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr. Infect. Dis. J. 27(12), 1073-1077 (2008).
121. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNg? PLoS One 3(12), e3901 (2008).